Dr. Bestvina on the KEYNOTE-407 Trial in Squamous NSCLC

Christine Bestvina, MD, assistant professor medicine, Department of Medicine, Hematology/Oncology, University of Chicago Medicine, discusses the phase III KEYNOTE-407 trial in squamous non—small cell lung cancer (NSCLC).

In the KEYNOTE-407 trial, investigators reported prolonged profession-free survival and overall survival with the addition of pembrolizumab (Keytruda) to carboplatin plus paclitaxel or nab-paclitaxel (Abraxane) in newly diagnosed patients with metastatic squamous NSCLC.

Notably, all patients, regardless of PD-L1 status, derived benefit from the combination with manageable toxicity, concludes Bestvina.